journal article·2026-06Open access

Non-competing Trop2 nanobody-based radiotheranostics for precision imaging and therapy of pancreatic cancer

Shushan Ge, Jinyu Shi, Tao Xu, Dingding Ai, Meng Zheng, Qingfeng Liu, Yan Wang, Shengming Deng, Liyan Miao

Abstract

Pancreatic cancer remains one of the most lethal malignancies, marked by late-stage detection, resistance to conventional therapies, and dismal overall survival. The transmembrane glycoprotein trophoblast cell-surface antigen 2 (Trop2) is frequently upregulated in pancreatic tumors and drives aggressive phenotypes, positioning it as a compelling target for precision oncology interventions. Here, we reported the development of a novel Trop2-specific nanobody-based theranostic pair, [ 68 Ga]Ga-T142 and [ 177 Lu]Lu-T142, capable of both non-invasive molecular imaging and targeted radionuclide therapy. The nanobody T142 was conjugated site-specifically with NODAGA or DOTA chelators, preserving its high Trop2-binding affinity alongside exceptional radiochemical purity and stability. In Trop2-positive pancreatic cancer xenograft models, [ 68 Ga]Ga-T142 demonstrated rapid and high-contrast tumor accumulation, minimal off-target uptake, and pharmacokinetic profiles characteristic of nanobody tracers. Epitope mapping revealed that T142 recognized a region distinct from that targeted by the clinically approved ADC Trodelvy, allowing accurate, interference-free quantification of Trop2 expression during ADC therapy. Longitudinal PET imaging detected early Trop2 downregulation post-ADC treatment, preceding observable tumor shrinkage, and showed superior performance to [ 18 F]FDG in monitoring therapeutic response. On the therapeutic front, [ 177 Lu]Lu-T142 elicited marked tumor regression in Trop2-positive models, while its combination with Trodelvy produced synergistic antitumor effects without significant systemic toxicity. Collectively, these results highlighted [ 68 Ga]Ga-T142 and [ 177 Lu]Lu-T142 as a highly promising Trop2-targeted theranostic platform, with strong potential for precise diagnosis, therapy monitoring, and personalized treatment of Trop2-expressing pancreatic cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Radiopharmaceutical Chemistry and Applications · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (35)

Show source-provided references
1. Pancreatic cancer: an increasing global public health concern
2. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
3. Cancer statistics, 2025
4. Pancreatic cancer: advances and challenges10.1016/j.cell.2023.02.014 ↗
6. Therapeutic developments in pancreatic cancer10.1038/s41575-023-00840-w ↗
7. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance10.1146/annurev-pathmechdis-031621-024600 ↗
8. Leveraging TROP2 antibody-drug conjugates in solid tumors10.1146/annurev-med-071322-065903 ↗
9. Targeting Trop-2 in cancer: recent research progress and clinical application
10. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial10.1016/j.annonc.2025.01.011 ↗
11. Dowlati A, Chiang AC, Cervantes A, Babu S, Hamilton E, Wong SF, Tazbirkova A, Sullivan IG, van Marcke C, Italiano A, Patel J, Mekan S, Wu T, Waqar SN. Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients with Extensive-Stage SCLC: Results from TROPiCS-03.
12. Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial10.1038/s41591-024-03269-z ↗
13. FDA approval summary: Datopotamab Deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-Positive, HER2-Negative breast cancer10.1158/1078-0432.CCR-25-1388 ↗
14. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 Study10.1200/JCO-24-01544 ↗
15. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial10.1016/j.annonc.2021.03.005 ↗
16. Trends in nanobody radiotheranostics10.1007/s00259-025-07077-6 ↗
17. Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years10.1186/s12951-024-02900-y ↗
18. Imaging and monitoring HER2 expression in tumors during HER2 antibody-drug conjugate therapy utilizing a radiolabeled site-specific single-domain antibody probe: 68Ga-NODAGA-SNA004-GSC10.1021/acs.jmedchem.4c00857 ↗
19. Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors10.1093/oncolo/oyae168 ↗
20. Theranostic application of 64Cu/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models10.1007/s00259-022-05954-y ↗
21. Preclinical Development and Comparison of [99mTc]Tc/[177Lu]Lu-Labeled Anti-Trop2 Fc-Fused Nanobodies as Pancreatic Cancer Theranostics10.1021/acs.molpharmaceut.5c01039 ↗
22. Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model10.1186/s41181-023-00235-x ↗
23. Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer10.1007/s00259-025-07106-4 ↗
24. ImmunoPET imaging of Trop2 expression in bladder cancer using [64Cu]Cu-NOTA-Trodelvy10.1021/acs.molpharmaceut.5c00069 ↗
25. Preclinical evaluation of a Trop2-Targeted peptide probe for PET imaging of triple-negative breast cancer10.1021/acs.analchem.5c05242 ↗
26. De novo discovery and preclinical evaluation of a novel peptide radiotracer for PET imaging of TROP-2 in non-small cell lung cancer10.1016/j.bioorg.2025.109204 ↗
27. In silico design and preclinical evaluation of a novel Trop2-targeted peptide tracer for PET imaging of tumors10.1007/s11426-025-2856-2 ↗
28. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers10.1007/s00259-023-06454-3 ↗
29. ImmunoPET imaging of Trop2 in patients with solid tumours10.1038/s44321-024-00059-5 ↗
30. 68Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancer10.1172/JCI185408 ↗
31. Single-Domain antibody probe with low renal uptake for claudin 18.2-Targeted PET imaging of gastric cancer: preclinical and pilot clinical evaluations10.2967/jnumed.125.271704 ↗
32. Pilot study of a novel nanobody 68Ga-NODAGA-SNA006 for instant PET imaging of CD8+ T cells10.1007/s00259-022-05903-9 ↗
33. [68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors10.1007/s00259-025-07326-8 ↗
34. Immuno-PET/CT imaging of Trop2 with [18F]AlF-RESCA-T4 Differentidtes Lung Cancel froc Inflammatiin
35. [99mTc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Pieclinicaf to pilot Clinical ptudy10.2967/jnumed.124.268564 ↗